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Abstract
Background: The first true demonstration of ether as an inhalation anesthetic was on October 16, 1846 by William
T.G. Morton, a Boston dentist. Ether has been replaced completely by newer inhalation agents and open drop
delivery systems have been exchanged for complicated vaporizers and monitoring systems. Anesthesia in the
developing world, however, where lack of financial stability has halted the development of the field, still closely
resembles primitive anesthetics.
Discussion: In areas where resources are scarce, patients are often not given supplemental intraoperative analgesia.
While halothane provides little analgesia, ether provides excellent intra-operative pain control that can extend for
several hours into the postoperative period. An important barrier to the widespread use of ether is availability. With
decreasing demand, production of the inexpensive inhalation agent has fallen.
Summary: Ether is inexpensive to manufacture, and encouraging increased production at a local level would help
developing nations to cut costs and become more self-sufficient.
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Background
First world anesthesiology delivers excellent care in a
safe, reliable environment. Safe medications, advanced
vaporizers and complex intra-operative monitoring are
standard in western operating rooms. Anesthesiology in
the developing world, however, is vastly different from
its western counterpart. In countries where health sys-
tems are plagued by diseases such as HIV/AIDS and
malaria, anesthesiology is seen as a low priority and
lacks the voice to demand access to better resources. In
Uganda, for example, only 23 % of anesthetists had the
minimal requirements for the safe provision of
anesthesia to an adult. An anesthetist is an anesthesia
provider, often a nurse or someone other than a phys-
ician. The items that this study found to be most fre-
quently unavailable were a pulse oximeter, a tilting
operating table, an oxygen source, and appropriately
sized endotracheal tubes. Furthermore, the authors also
found that running water was not always present and
intravenous fluids were not readily available. Shockingly,
only 16 % of government hospitals and 50 % of mission
hospitals were able to deliver safe anesthesia for adults
[1]. It is in this context, that a case is made for the reex-
amination and promotion of ether as the primary inhal-
ation general anesthetic of the developing world.
Discussion
Historical perspectives
The discovery of ether for the use as an anesthetic was
in 1846 which marked the birth of a modern age in
anesthesiology. Although its use has been abandoned in
the developed world, ether was safely and effectively
used as an inhalation anesthetic for over one hundred
years. Prior to the middle of the 19th century and the
discovery of ether, surgery was a rare and gruesome pro-
cedure. One of the most common operations was ex-
tremity amputation. There the surgeon used saws and
knives to remove an appendage and scalding irons to
cauterize the wound. Before the discovery of anesthesia,
the sound of patients thrashing and screaming vibrated
throughout the operating rooms [2]. They resorted to a
variety of methods to control the patient’s pain including
alcohol, opiates, ice, and various distractions.
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Ether (diethyl ether) was first prepared in 1540 by
Valerius Cordus, a Prussian botanist. Cordus produced
the compound, known as “sulfuric ether” at the time, by
distilling sulfuric acid (oil of vitriol) with fortified wine
to make an “oleum vitrioli dulce” (sweet oil of vitriol)
[3]. Despite this early synthesis, ether was rarely used
over the next three decades. In fact, it’s only routine
consumption was as a recreational drug among poor
Britians who sometimes drank an ounce of ether when
traditional alcohol was not available. American students
adopted a variation of this practice in the “ether frolics”
of the early 1800s to achieve a feeling of euphoria. Par-
ticipants would hold ether soaked towels to their faces
until losing consciousness.
Ether was first made use of as a general anesthetic by
Dr. Crawford Williamson Long on March 30, 1842.
Long was a physician and pharmacist who learned about
ether while studying medicine in college. In 1842, Long
removed a tumor from the neck of a patient who was
under the effects of ether anesthesia. Unfortunately, the
successful and unprecedented use of anesthesia during
surgery was not credited to Long due to his laxity in
publishing the results of the surgery until several years
later.
The first true demonstration of ether as an inhalation
anesthetic was on October 16, 1846 by William T.G. Mor-
ton, a Boston dentist. He discovered the anesthetic prop-
erties of ether in his search to provide patients with relief
from painful dental procedures [4]. Prior to 1846,
anesthesia was not used during surgical procedures and
patients often avoided surgical intervention at all cost.
Additionally, prior to the monumental events of 1846,
Morton attended a public demonstration of the anesthetic
properties of nitrous oxide given by Horace Wells. Wells,
also a dentist, administered nitrous oxide to a patient and
then extracted a wisdom tooth. Unfortunately, the patient
did not appear to be fully anesthetized and the public
deemed the demonstration to be a failure.
The exhibition furthered Morton’s interest in inhal-
ation anesthetics and led him to consult a professor
of chemistry at Harvard Medical School, Charles A.
Jackson [4]. Jackson recommended a trial of sulfuric
ether as an alternative to nitrous oxide, commonly
known as “laughing gas”. Morton began experiment-
ing with the ether and learned that a drop on the
skin produced local analgesia. Further investigation
with inhaled ether revealed that the agent was more
versatile than inhaled nitrous oxide. As opposed to
nitrous oxide, bottles of ether could be transported
easily and the volatility of the drug permitted effective
inhalation. In addition, the concentration of the drug
required for surgical anesthesia was so low that the
patients did not become hypoxic when breathing ether va-
porized in air which is an advantage compared to nitrous
oxide. Morton, who had entrepreneurial aspirations,
quickly became convinced that ether was a suitable sur-
gery anesthetic for hospital surgery and knew the signifi-
cance of ether as a surgical anesthetic. He also knew that
since ether has been available for centuries, it could not be
patented, so Morton added some odor-masking impurities
to ether, and called the concoction Letheon.
As a result of Morton’s “success”, he began to promote
the use of ether in his dental practice. His success also
prompted a demonstration at Harvard Medical School.
On October 16, 1846, Morton publicly administered in-
haled ether to a patient at Massachusetts General Hos-
pital which took place in an amphitheater now known as
the “Ether Dome”. The patient was successfully anesthe-
tized and the surgeon, Dr. John Warren, removed a
tumor from Mr. Gilbert Abbot’s neck. The patient had
muttered as if in a semi-conscious state during the oper-
ation and after the surgery was complete, he stated that
the pain was considerable, though mitigated. On the fol-
lowing day, the vapor was administered to another pa-
tient with complete success [4]. The public
demonstration of ether anesthesia signaled the birth of
the field of anesthesiology as a specialty. Ether
anesthesia was adopted rapidly around the world and
surgical anesthesia and analgesia became an accepted
standard in surgical care.
Morton kept the true composition of Letheon a secret
with the hopes of becoming wealthy. However, it was
not long before surgeons recognized the smell of
Letheon and associated it with ether. Morton attempted
to fight the widespread use of ether which even included
petitioning Congress for two decades to award him as
the discoverer of ether. Nonetheless, Congress was
knowledgeable of ether’s ancient origins and no monet-
ary reward was given to Morton.
Oliver Wendell Holmes Sr. created the term anesthesia
that was derived from the Greek word anaisthēsia
meaning “lack of sensation” [5]. Holmes was a professor
of anatomy and physiology at Harvard and had rejoiced
saying that “The knife is searching for disease, the pul-
leys are dragging back dislocated limbs, nature herself is
working out the primal curse which doomed the tender-
est of her creatures to the sharpest of her trials, but the
fierce extremity of suffering has been steeped in the wa-
ters of forgetfulness, and the deepest furrow in the knot-
ted brow of agony has been smoothed forever [6].”
Ether was safe, easy to use, and remained the standard
general anesthetic until the 1960s when the fluorinated
hydrocarbons (halothane, enflurane, isofluorane and
sevoflurane) came into common use. Although these
newer agents reduced the postoperative nausea, vomit-
ing and flammability that were problematic with ether,
they were expensive to produce and included a host of
undesirable side effects.
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Anesthetics used today are almost unrecognizable from
anesthetics used in the late 1800s. Ether has been replaced
completely by newer inhalation agents and open drop de-
livery systems have been exchanged for complicated va-
porizers and monitoring systems. Anesthesia in the
developing world, however, where lack of financial stability
has halted the development of the field, still closely resem-
bles primitive anesthetics.
Anesthesia in undeveloped countries
Shortages of personnel who are adequately trained to ad-
minister anesthetics, drugs, and equipment are com-
monplace in third world countries. Operating room
conditions are primitive by U.S. standards [7]. Pulse oxi-
meters, tilting operating tables and appropriately sized
endotracheal tubes are often unavailable. A functional
oxygen source, running water and electricity are often
unreliable. Furthermore, there are an inadequate number
of anesthesiologists in third world nations and anesthesia
is also usually delivered by non-physician anesthetists
and nurses under the direction of a surgeon. These pro-
viders typically have minimal or no formal training in
medicine and usually even less training in anesthesiology
[1, 8]. A recent study in Uganda, for example, found that
among 91 anesthesia providers, 85 % attended training
courses of only 1 year to 19 months duration. The same
study found that there are only 13 anesthesiologists and
330 non physician anesthetists for the entire Ugandan
population of 27 million. By comparison, there are ap-
proximately 12,000 anesthesiologists for a population of
60 million in the United Kingdom [1].
In an attempt to provide anesthesia, developing coun-
tries have had to make cost saving adjustments. “One
time use” items such as endotracheal tubes are reused
and recycled, often becoming unsafe because of balloon
rupture after a few uses [9]. Expensive anesthetic vapor-
izers and circle systems, the mainstay of western
anesthesiology have been largely abandoned. These de-
vices are not only expensive, but they are also costly to
maintain. Service, parts, and appropriate safety training
eparts are rarely available.. In addition, these vaporizers
are dependent on a continuous supply of oxygen, which
is not reliably available in developing nations.
Consequently, “draw-over anesthesia” is extensively
utilized. In draw-over anesthesia, the carrier gas (atmos-
pheric air) is drawn over the volatile liquid (anesthetic
agent) by the patients’ respiratory efforts. Drawover sys-
tems are simple to assemble and use. Most importantly,
drawover technique is safe for patients.
Anesthetic drugs, common in western anesthesiology,
are rarely available in developing nations. Sevofluorane,
desfluorane and isofluorane, the fluorinated hydrocar-
bons that are the major inhalation agents of the west,
are unavailable in developing countries. These agents are
both expensive and require extensive equipment for de-
livery. Instead, halothane is the most widely used volatile
agent in developing nations [8]. Ether is also used, but
its use is limited due to decreased availability and flam-
mability. Substituting ether for halothane in developing
nations, most importantly in those already using draw-
over anesthesia, could both save money and improve the
safety of surgical anesthesia.
Ether versus halothane
Although abandoned in western anesthesia, ether has
long been known as a relatively safe and inexpensive
anesthetic. Halothane costs approximately U.S. $140 per
liter (U.S. $0.14 per ml). In one study, Eltingham, using
a Glostavent Anesthetic Machine with halothane as the
sole agent, found that the mean use of halothane was
16 ml per hour. This results in a cost of U.S. $2.24 per
hour of use. While this cost is relatively minor by west-
ern standards (approximately a tenth of the price of
Sevoflurane), it is still a considerable portion of the small
budget of anesthesiology departments in developing na-
tions. In a study conducted in 1994 in Malawi, halothane
accounted for a quarter of the entire anesthesiology de-
partment budget [8].
In contrast, ether costs a mere U.S. $10 per liter (ap-
proximately U.S. $0.01 per ml). Using the same calcula-
tions as above, this would lead to a cost of U.S. $0.16
per hour of use (a U.S. $2.08 per hour savings compared
to halothane). The cost difference could save struggling
anesthesiology departments thousands of dollars each
year.
Hospitals located in rural areas could also save money
by increasing the use and production of ether. While
halothane is relatively expensive to produce and must be
manufactured in large factories and then transported to
rural health care centers, ether can be easily and cheaply
produced from ethanol at a local level. Purchasing lo-
cally manufactured anesthetic ether could have signifi-
cant effects by decreasing cost, supporting local
economies, and making rural hospitals in developing na-
tions more self-sufficient.
Both halothane and ether can be administered easily
using drawover anesthetic techniques. Halothane, how-
ever, is a relatively unsafe agent to use without intra-
operative monitoring. As mentioned earlier, developing
nations rarely have either a reliable oxygen source or
electricity. As a result, intra-operative monitoring and
intervention with supplemental oxygen are not possible.
Halothane depresses both the ventilatory drive and car-
diac output making supplemental oxygen and cardiac
monitoring crucial. Ether, on the other hand, acts as a
sympathomimetic agonist, stimulating cardiac output,
respiratory rate, and causing bronchodilation. While not
ideal, it is therefore safe to use ether when supplemental
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oxygen, endotracheal intubation and cardiac monitoring
aren’t available.
Finally, the side effects of ether anesthesia are rela-
tively minor when compared with those of halothane.
Halothane hepatitis is a well-documented toxicity in pa-
tients exposed to the drug. Although relatively rare (af-
fecting only 1/10,000 patients), halothane hepatitis has a
mortality rate of 50 % [10]. In addition, halothane has
been known to cause cardiac arrhythmias as well as fatal
bradycardia. Due to the concerns surrounding its hep-
atotoxicity, halothane has been primarily eliminated for
use in adults in the United States and many other coun-
tries. Halothane was eventually replaced by safer newer
volatile anesthetics. However, in countries with different
medico legal climates, halothane still plays a vital role
due to its relatively low cost. For example, halothane is
still being used as the main anesthetic in more than
80 % of the hospitals in Iran. As a result, increasing
numbers of halothane hepatitis is being reported in Iran
and among other countries still using halothane [11].
Ether, on the other hand, is a relatively safe agent with
its main side effect being postoperative nausea and
vomiting.
The major problem with ether is its extreme flamma-
bility, especially in the presence of oxygen. Ether is ex-
tremely volatile and has a low boiling point, two
characteristics which make it prone to explosion. The
number of surgical fires in 1960 (when ether was the
primary inhalation anesthetic used in the United States),
was reported at one in approximately 100,000 anesthesia
[12]. Therefore, the number of fires caused by ether is
therefore relatively small.
There are relatively easy to implement precautions
that operating rooms in developing countries can
mandate to combat the ether’s flammability. First, open
flames, such as those provided by alcohol lamps, Bunsen
burners, matches, and smoking must be prohibited in
rooms where anesthetics are either administered or
present. Next, the use of incandescent or high frequency
cautery or coagulation within a distance of two feet from
the mouth of a patient receiving flammable anesthetics
must be prohibited unless a rubber sheet and wet drapes
are properly applied. Last, ether should be stored in ori-
ginal cans or dark glass bottles to avoid explosions due
to the effect of sunlight [12].
Barriers to widespread use
While halothane is currently the most widely used vola-
tile agent in the developing world, ether still has a place
in some counties. Unfortunately, even this use is threat-
ened by decreased availability of ether and lack of med-
ical provider education in ether anesthesia. Lack of
funding to anesthesia departments in developing nations
has led many budding anesthesiologists to seek training
in wealthier countries. Unfortunately, education in ether
anesthesia and drawover techniques has completely van-
ished from the curriculum of the first world. This leads
to medical migration; anesthesiologists from developing
countries who are trained abroad often remain in the
countries where they are educated after attaining their
training. In addition, volunteer practitioners who travel
to developing nations from the west are unfamiliar with
ether and drawover techniques and often find them-
selves unequipped to deal with the realities of delivering
anesthesia in the developing world. Anesthetic ether has
also become less available in recent years. Falling de-
mand for the inexpensive agent in developed nations has
led many manufacturers to claim a lack of profitability
and to halt production [1].
Summary
Diethyl ether anesthesia deserves to be reconsidered for
widespread use in the developing world. In countries
that lack the resources to fund anesthesiology develop-
ment, ether could greatly improve the safety and eco-
nomics of anesthesia practices.
Developing nations rarely have the personnel and
equipment to provide safe anesthesia. Anesthesia is
most commonly delivered by non-physicians who have
little or no formal training. Cardiac monitors, pulse-
oximeters, supplemental oxygen and endotracheal in-
tubation are rarely available [1], and anesthesia is deliv-
ered using drawover techniques. Halothane, the most
common inhalation anesthetic in the developing world,
is a potent agent and, without monitoring equipment
and trained providers, can lead to significant patient
morbidity and mortality. Ether, on the other hand is
nontoxic to the cardiovascular system and it does not
depress respiratory activity. It is safe to use by anesthe-
tists who have not received formal training and without
complicated monitoring, supplemental oxygen and
endotracheal intubation. Ether has the added benefit of
providing surgical analgesia. In areas where resources
are scarce, patients are often not given supplemental in-
traoperative analgesia. While halothane provides little
analgesia, ether provides excellent intra-operative pain
control that can extend for several hours into the post-
operative period.
Finally, ether is inexpensive and would provide significant
cost savings in countries where halothane represents a
major portion of anesthesiology department budgets. While
halothane costs approximately U.S. $140 per liter (U.S.
$0.14 per ml), anesthetic ether can be purchased for as little
as U.S. $10 per liter (U.S. $0.01 per mL). Assuming a mean
use of 16 ml per hour, this leads to a cost savings of ap-
proximately U.S. $2.24 per hour of use. Promoting ether
anesthesia for widespread use in developing countries could
lead to enormous savings, which could be channeled into
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improving training, equipment and the overall conditions
of anesthesia services.
While it has been shown that ether anesthesia is safe
and inexpensive, there are significant barriers to its
widespread use. Anesthesiologists in developed nations
are completely unfamiliar with the agents and the draw-
over techniques required for its delivery. As many anes-
thesiologists from developing countries are trained in
the west, the lack of education in ether anesthesia and
relevant techniques leaves them unprepared to practice
in their home countries. Similarly, volunteer anesthesiol-
ogists from developed nations seeking to help under
resourced hospitals find themselves lacking in the skills
necessary to deliver anesthesia in a new environment.
The solution to this problem is twofold. First, educa-
tion in drawover anesthesia, using ether as the primary
inhalation agent, should be reinstated as part of the edu-
cational curriculum in developed countries. Encouraging
familiarity with these anesthetic techniques would allow
all anesthesiologists to be proficient in the delivery of
anesthesia in developing countries. Second, academic in-
stitutions in developed nations should be encouraged to
establish joint training program in developing countries.
Such programs would benefit both sponsor institutions
and the under resourced areas where they are located.
Anesthesiologists in developed countries would receive a
broader education in anesthetic technique and those in
developing countries would receive proficient training in
their home countries; thereby halting medical migration.
The last barrier to the widespread use of ether is avail-
ability. With decreasing demand, production of the inex-
pensive inhalation agent has fallen. Ether is inexpensive
to manufacture, and encouraging increased production
at a local level would help developing nations to cut
costs and become more self-sufficient.
The widespread use of ether anesthesia in developing
countries would improve patient safety, cut costs and
help struggling health care systems become more self-
sufficient. In 2007, the British Medical Journal asked
subscribers to name the most-significant medical devel-
opments since 1840, and unsurprisingly, anesthesia was
among the top three which also included antibiotics and
modern sanitation.
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